Evidence map›Paper›PMID 30034236›Full record

ArticleInternational journal of nanomedicine2018

Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.

Xin Li, Xiaoqian Jia, Hu Niu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xin LiDepartment of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China.
Xiaoqian JiaDepartment of General Surgery 2, The Fourth People's Hospital of Jinan, Jinan, Shandong, China, niuhu0678@126.com.
Hu NiuDepartment of General Surgery 2, The Fourth People's Hospital of Jinan, Jinan, Shandong, China, niuhu0678@126.com.
Fourth People’s Hospital of Jinan · CNHeze Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P) H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells. PURPOSE: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy. PATIENTS AND

methodsLapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method.

resultsThe well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC).

conclusionLDNLC might be a promising platform for effective breast cancer therapy.

Indexed as

Adenosine TriphosphateAnimalsAntineoplastic AgentsBreast NeoplasmsCell DeathCell SurvivalColloidsDoxorubicinDrug CarriersDrug LiberationDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleHemolysisHumansLipidsAdenosine TriphosphateAntineoplastic Agentsbeta-lapachoneColloidsDoxorubicinDrug CarriersLipidsNaphthoquinonesbreast cancerdoxorubicinmultidrug resistancenanostructured lipid carriersβ-lapachone

Identifiers

PMID30034236
PMCPMC6047616
OpenAlexW2838017814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.